Membrane lipid rafts provide a specialized microenvironment enriched with sphingolipids and phospholipids containing saturated fatty acids and serve as a platform for various intracellular signalling pathways. PtdGlc (phosphatidylglucoside) is a type of glycophospholipid localized in the outer leaflet of the plasma membrane. Owing to PtdGlc's unique fatty acid composition, exclusively composed of C 18:0 at sn-1 and C 20:0 at sn-2 of the glycerol backbone, it tends to form PGLRs (PtdGlcenriched lipid rafts). Previously, we demonstrated that PGLRs reside on the cell surface of astroglial cells from fetal rat brain [Nagatsuka, Horibata, Yamazaki, Kinoshita, Shinoda, Hashikawa, Koshino, Nakamura and Hirabayashi (2006) Biochemistry 45, [8742][8743][8744][8745][8746][8747][8748][8749][8750]. In the present study, we observed PGLRs in astroglial lineage cells at mid-embryonic to early-postnatal stages of developing mouse cortex. This suggests that PGLRs are developmentally correlated with astroglial differentiation during fetal cortical development. Our cell culture studies with multipotent neural progenitor cells prepared from fetal mouse telencephalon demonstrated that treatment with EGF (epidermal growth factor) or anti-PtdGlc antibody caused recruitment of EGFRs (EGF receptors) into lipid raft compartments, leading to activation of EGFRs. Moreover, the activation of EGFRs by antibody triggered downstream tyrosine kinase signalling and induced marked GFAP (glial fibrillary acidic protein) expression via the JAK (Janus kinase)/STAT (signal transducer and activator of transcription) signalling pathway. These findings strongly suggest that PGLRs are physiologically coupled to activated EGFRs on neural progenitor cells during fetal cortical development, and thereby play a distinct role in mediating astrogliogenesis.
INTRODUCTION
The lipid raft hypothesis has had a wide impact on the field of biology and has provided profound insight into membrane dynamics in living cells [1] . Increasing evidence has unveiled the multiple mechanisms involving lipid rafts as functional membrane domains for cell-cell interactions and signal transduction [2, 3] .
In mammalian neural cells, membrane lipid rafts serve as key assembly and sorting platforms for cell-cell interactions or signal transduction complexes and modulate multiple cellular processes, such as axonal growth and guidance of neuronal growth cones [4] , cytokine/growth factor receptor signalling [5, 6] , neuron-glia interactions [7, 8] , neuronal survival and death, and many more [9, 10] .
Recent lipid raft research has identified PtdGlc (phosphatidylglucoside) as a unique cell-surface glycophospholipid that was originally found in human umbilical cord red blood cells and subsequently in HL60 cells, a human promyelocytic cell line [11] . We demonstrated that PGLRs (PtdGlc-enriched lipid rafts) mediate granulocytic differentiation of HL60 cells by recombinant anti-PtdGlc univalent antibody (rGL-7) treatment [11] . In order to study the biochemical nature, histological distribution and physiological roles of PGLRs in mammalian tissues, we produced a mouse mAb (monoclonal antibody) called DIM21 [12] . With the help of this antibody, we detected and extracted endogenous PtdGlc from fetal rat brains and succeeded in determining its complete chemical structure [13] . Very interestingly, PtdGlc consists solely of saturated fatty acyl chains: C 18:0 at sn-1 and C 20:0 at the sn-2 position of the glycerol backbone, denoting its localization in DIMs (detergent-insoluble membranes) or lipid rafts.
In the present paper, we report that PGLRs are enriched in cells of astroglial lineage in developing mouse CNS (central nervous system) and that they are potentially involved in astrogliogenesis in mouse cerebral cortex by physiologically coupling to EGFRs [EGF (epidermal growth factor) receptors] during late-embryonic Abbreviations used: BCA, bicinchoninic acid; bFGF, basic fibroblast growth factor; BLBP, brain lipid-binding protein; BrdU, bromodeoxyuridine; CNPase, 2 ,3 -cyclic-nucleotide 3 -phosphodiesterase; CNS, central nervous system; CNTF, ciliary neurotrophic factor; CP, cortical plate; DIM, detergent-insoluble membrane; DIV, days in vitro; DMEM, Dulbecco's modified Eagle's medium; E, embryonic day; EGF, epidermal growth factor; EGFR, EGF receptor; GFAP, glial fibrillary acidic protein; GLAST, glutamate-aspartate transporter; GLUT1, glucose transporter 1; gp130, glycoprotein 130; HBSS, Hanks balanced salt solution; HRP, horseradish peroxidase; JAK, Janus kinase; LC, liquid chromatography; LC-MS (n) , negative-ion-mode LC-MS; LIF, leukaemia inhibitory factor; mAb, monoclonal antibody; MAP2, microtubule-associated protein 2; MβCD, methyl-β-cyclodextrin; MBP, myelin basic protein; MS/MS, tandem MS; NG2, nerve/glial antigen 2; NPC, neural progenitor cell; P, postnatal day; PFA, paraformaldehyde; PHGDH, phosphoglycerate dehydrogenase; PtdGlc, phosphatidylglucoside; PGLR, PtdGlc-enriched lipid raft; RT, reverse transcription; STAT, signal transducer and activator of transcription; SVZ, subventricular zone; TuJ1, class III β-tubulin; VZ, ventricular zone. 1 To whom correspondence should be addressed (email hirabaya@riken.jp).
stages of development. In our cell culture studies, multipotent NPCs (neural progenitor cells) from embryonic cortex treated with DIM21 induced rapid recruitment and activation of EGFRs followed by enhanced GFAP (glial fibrillary acidic protein) expression. To clarify the underlying physiological mechanism, we examined the physical association between PGLRs and EGFRs, employing cytological analyses and MβCD (methyl-β-cyclodextrin), a membrane cholesterol-removing agent. We also studied the molecular mechanisms leading to the EGFR-mediated differentiation of PGLR-expressing cortical progenitor cells to astroglial cells. Our findings provide evidence that PGLRs serve as a selective signalling platform for EGFR signalling at the onset of gliogenesis in developing cortex. We discuss the biochemical and functional characteristics of PtdGlc/PGLRs and their correlation with astroglial differentiation in the developing cerebral cortex of mice.
MATERIALS AND METHODS

Materials
Chemically synthesized PtdGlc was prepared as described previously [14] . Monoclonal antibody DIM21 was produced and purified as described in [12, 15] . MβCD, poly-L-ornithine, and poly(2-hydroxyethylmethacrylate) were purchased from Sigma-Aldrich. The tyrphostins AG490 and PD168393 were obtained from Calbiochem. Growth factors EGF and bFGF (basic fibroblast growth factor) were from BD Biosciences and R&D Systems respectively. DMEM (Dulbecco's modified Eagle's medium)/F12, HBSS (Hanks balanced salt solution), PBS, antibiotics for cell culture and NGS (normal goat serum) were from Gibco. Bovine plasma fibronectin and TRIzol ® reagent were from Invitrogen. Triton X-100 detergent and BCA (bicinchoninic acid) protein assay reagents were from Pierce Biotechnology. BrdU (bromodeoxyuridine) and protease/phosphatase inhibitors were purchased from Roche Diagnostics. Chemiluminescent reagents (ECL ® Plus) were from GE Healthcare.
Animals
C57BL/6J mice were treated and killed according to the Institute Animal Experiment Handbook approved by the Animal Experiment Committee at RIKEN. The presence of a vaginal plug was marked as embryonic day 0.5 (E0.5), and the day of birth was designated postnatal day 0 (P0).
TLC
Total lipids were extracted from freeze-dried E14.5 mouse brains with chloroform/methanol (2:1, v/v) followed by chloroform/ methanol/water (5:8:3, by vol.). The extracts obtained were dried with a stream of nitrogen gas and partially purified using iatrobeads column chromatography (approx. 5 mm × 5 cm) preequilibrated with chloroform/methanol (4:1, v/v). After washing with chloroform/methanol (4:1 and then 3:1, v/v), the PtdGlcenriched fraction was eluted with chloroform/methanol (2:1, v/v). The fractions obtained were dried, dissolved into chloroform/ methanol (2:1, v/v) (10 μl/mg of dried tissue), subjected to HPTLC (high-performance TLC) (Merck) or Polygram Sil G-plate (Macherey-Nagel) chromatography developed with chlorofom/methanol/ethanoic (acetic) acid/water (65:35:4:4, by vol.) and detected either chemically with orcinol reagent or by DIM21 immunolabelling respectively. Two-dimensional TLCs were first developed with the same acidic solvent and subsequently chloroform/methanol/2.5 M ammonium hydroxide (60:35:8, by vol.). PtdGlc was visualized by DIM21 immunolabelling as described previously [13] .
LC (liquid chromatography)-MS
Nano-LC-MS (n) (negative-ion-mode nano-LC-MS) analysis of PtdGlc was performed using a NanoFrontier L (Hitachi HighTechnologies) equipped with an Inertsil SIL-100A Si column (3 μm particles, 0.075 mm internal diameter and 150 mm length; GL Science) [16] , and an Upchurch Scientific M-435 microinjection valve. HPLC was run at room temperature (25 • C).
Cells and tissue culture
NPCs were prepared from proliferative cell spheres derived from neural stem/progenitor cells located in E14.5 mouse telencephalons. Briefly, the telencephalons were removed (olfactory bulbs and meninges were discarded) and washed in cold HBSS. The tissue was gently dissociated by trituration in cold serum-free culture medium composed of N2-supplemented DMEM/F12 (1:1) containing 0.6 % D-glucose, 20 ng/ml EGF, 10 ng/ml bFGF and penicillin/streptomycin, as described previously [17] , with minor modifications. The obtained cells were sieved through a 40 μm pore size nylon membrane cell strainer (BD Falcon) and plated on to non-adherent poly(2-hydroxyethylmethacrylate)-coated dishes at a density of (0.5-1) × 10 4 cells/cm 2 . The medium was supplied with the same doses of growth factors every 2 days. Cell spheres were usually passaged three times after primary culture to remove non-proliferative cells. Finally, the cells were re-plated on to poly-L-ornithine/fibronectincoated dishes in the presence of bFGF at a density of 10 5 cells/cm 2 , grown in a 5 % CO 2 incubator at 37
• C for 2 DIV (days in vitro) and incubated further for another 2 DIV in the presence of DIM21 with or without reagents of interest, unless stated otherwise.
Preparation of tissue sections
For whole-body and brain cryosections, extirpated embryos were freshly obtained, frozen immediately with powdered solid CO 2 , and sliced with a cryostat (20 μm; Microm HM560). The sections were mounted on glass slides, dried and fixed with 4 % (w/v) PFA (paraformaldehyde) in 0.1 M sodium phosphate buffer (pH 7.4) for 10 min before immunolabelling. For conventional brain sections, fetal brains were fixed by immersion in 4 % (w/v) PFA for 3 h at room temperature; postnatal brains were perfused transcardially with cold 4 % PFA. After fixation, brains were sliced with a vibrating-blade microtome (50 μm; Leica VT1000S).
Immunofluorescent labelling
Sections were immunolabelled at 4
• C overnight with DIM21 mAb with or without guinea-pig anti-BLBP (brain lipidbinding protein), rabbit anti-GLAST (glutamate-aspartate transporter), rabbit anti-PHGDH (phosphoglycerate dehydrogenase), guinea-pig anti-GLUT1 (glucose transporter 1) (gifts from Professor Masahiko Watanabe, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Japan), rabbit anti-GFAP (N1506; Dako), rabbit anti-TuJ1 (class III β-tubulin) (MRB-435P; Covance), rabbit anti-MAP2 (microtubule-associated protein 2) (AB5622; Chemicon), rabbit anti-MBP (myelin basic protein) (AB980; Chemicon), chicken anti-CNPase (2 ,3 -cyclic-nucleotide 3 -phosphodiesterase) (AB9342; Chemicon) or rabbit anti-NG2 (nerve/glial antigen 2) (AB5320; Chemicon) antibodies. The sections were then incubated with appropriate species-specific secondary antibodies conjugated with Alexa Fluor ® 488, Alexa Fluor ® 562 or Alexa Fluor ® 633 (2 μg/ml; Molecular Probes) for 1 h at room temperature. Afterwards, the sections were examined with a fluorescence microscopy system (Keyence BZ-9000) or with confocal laser-scanning microscopes (Olympus FV1000). Cultured NPCs fixed with 4 % (w/v) PFA for 30 min and labelled with DIM21, anti-GFAP, anti-TuJ1, rabbit anti-EGFR (sc-03; Santa Cruz Biotechnology) or rabbit anti-gp130 (glycoprotein 130) (sc-656; Santa Cruz Biotechnology) antibodies at 4
• C overnight were subjected to secondary antibody reactions as described above.
Semi-quantitative RT (reverse transcription)-PCR
Total RNA was isolated from cultured NPCs treated with 10 μg/ml DIM21 for 0.3 to 360 min by TRIzol ® reagent, according to the manufacturer's instructions, and was reversetranscribed using a cDNA Reverse Transcription Kit (Applied Biosystems). Subsequently, each cDNA (200 ng) was subjected to PCR using KOD-Plus-DNA polymerase (Toyobo) according to the following programme: 94
• C for 2 min, 30 cycles at 94
• C for 15 s, 74
• C for 30 s and 68
• C for 30 s, and 72
• C for 7 min. The resulting oligonucleotides were used as the sense/antisense primers to detect Egfr cDNA: 5 -CGACCCCACAGGTGCTGT-AACAGAGGACAA-3 (T m 80.0
• C), 3 -TGGATCCAGAGTGC-AGGGCTGTTAAACCCA-5 (T m 79.9
• C). The length of the amplified fragments was 264 bp.
Quantitative RT-PCR
Total RNA was isolated from cultured NPCs treated with 0.1-10 μg/ml DIM21 and grown in a 5 % CO 2 incubator at 37
• C for 2 DIV. Mouse myeloma IgM κ antibody (M3795; Sigma-Aldrich) at 10 μg/ml was used for mock samples. The isolated RNA was reverse-transcribed using a cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative PCR was performed with an ABI-Prism 7900HT Sequence Detection System (Applied Biosystems) and a TaqMan Gene Expression Assay Kit optimized for mouse Gfap (#4331182; Applied Biosystems). The assay data were obtained from three independent experiments. The expression level of Gfap mRNA was normalized to that of Gapdh (glyceraldehye-3-phosphate dehydrogenase) mRNA. Data were processed with an ABI Sequence Detection System and subsequently analysed with Bonferroni's multiple comparison tests.
Western blotting
Cultured NPCs prepared as above were incubated either with 0.1-10 μg/ml DIM21 or 10 μg/ml mouse myeloma IgM κ antibody in the absence of extrinsic growth factors for 2 DIV. In some experiments, reagents such as MβCD, tyrphostin AG490 or tyrphostin PD168393 were added to cultures before and/or during the DIM21 treatment. The cultures were lysed either in 100 μl of lysis buffer containing 20 mM Tris/HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, protease/phosphatase inhibitors and 1 % Triton X-100 or in an appropriate volume of sample buffer (30 μl/cm 2 ) containing 50 mM Tris/HCl (pH 6.8), 5 % (w/v) SDS and 10 % (v/v) glycerol to kill the cells instantly. Protein concentrations were determined with a BCA Protein Assay Kit using BSA as a standard. The cell extracts were separated via SDS/7.5-10 % PAGE, and separated proteins were transferred on to PVDF membranes (GE Healthcare). The membranes were probed with the following antibodies: anti-GFAP, anti-TuJ1, mouse anti-GAPDH (MAB374; Chemicon), anti-gp130, rabbit anti-EGFR (#2232; Cell Signaling Technology), rabbit anti-phospho-EGFR ( 
RESULTS
PtdGlc is an endogenous lipid component in fetal mouse brain
The occurrence of PtdGlc in fetal mouse brain was examined biochemically using three analytical methods. First, total lipid extracts from E14.5 mouse brains were subjected to TLC analysis. As with fetal rat brains [13] , there was an orcinol-positive glycolipid that migrated to the position identical with that of synthetic PtdGlc ( Figure 1A ). We then analysed total lipid extracts employing nano-LC-MS (n) . LC-MS analysis demonstrated a single peak at m/z 893. (n) analysis provided biochemical evidence that PtdGlc is present in fetal mouse brain just as in fetal rat brain ( Figure 1C ). Finally, we performed two-dimensional TLC immunolabelling on the total lipid extracts ( Figure 1D ) to verify the presence of PtdGlc and the binding specificity of DIM21 mAb to endogenous PtdGlc. Figure 1 (D) shows that DIM21 recognized PtdGlc as the sole compound which migrated to the position corresponding to synthetic PtdGlc on the TLC plate. This finding is in good agreement with our recent studies concerning synthetic PtdGlc and its derivatives, demonstrating DIM21's high antigen specificity [15] . Together, these results demonstrate that PtdGlc is present in fetal mouse brain as a native lipid component.
PtdGlc is located in lipid raft-like structures on glial cell membranes
To examine PtdGlc distribution in vivo, we labelled E14.5 whole-body cryosections using DIM21. We observed intense DIM21 labelling in restricted regions, including cerebral cortex, hippocampus, olfactory epithelium and vestibulocochlear ganglion in the nervous system (Figures 2A and 2B ). The medulla oblongata was also weakly labelled.
In developing cerebral cortex, DIM21 intensely stained radial glial cells located in the germinal zones ( Figure 2C ). Most notably, DIM21 labelled cell surfaces and radial processes in a punctate fashion ( Figure 2D ), suggesting that PtdGlc is localized in domain-like plasma membrane structures on radial glial cells as observed previously in cultured rat astroglial cells [13] . Treating sections with an organic solvent mixture composed of chloroform and methanol (2:1, v/v) completely abolished the domain-like DIM21 labelling ( Figures 2E and 2F) , indicating that the DIM21 antigen is lipid-like. Taken together with our previous finding that PtdGlc is detergent-insoluble [11] , these immunohistological observations suggest strongly that PtdGlc resides in lipid raft-like structures in vivo. Moreover, these PGLRs are abundantly present in radial glial cell membranes in developing cerebral cortex. 
PGLRs are enriched in cells of astroglial lineage in developing cerebral cortex
To gain insight into the physiological role of PGLRs in developing cortex, we examined the expression profile of PGLRs in embryonic and early-postnatal cerebral cortices by immunohistochemistry. At early-E12.5, DIM21 labelled the entire cortex, where radial glia-specific antigens, such as BLBP [18] , GLAST [19] and PHGDH [20] , were expressed ( Figure 3A and see Supplementary Figures S1A and S1B at http://www. BiochemJ.org/bj/419/bj4190565add.htm). At mid-E14.5, DIM21 labelling overlapped well with these radial glial markers in the germinal VZ (ventricular zone) and SVZ (subventricular zone) ( Figure 3B and see Supplementary Figures S1C and S1D). Newborn cortical neurons were DIM21-positive in the VZ/SVZ, but were DIM21-negative in CP (cortical plate), where they accumulate following migration ( Figure 3C ). After late-E18.5, although the DIM21 labelling was absent from the VZ/SVZ ( Figure 3D and see Supplementary Figures S1E and S1F), DIM21-labelled cells began to appear in the CP ( Figure 3E ), where they weakly expressed the astroglial marker GFAP ( Figure 3F ). Moreover, cell fate tracing with the thymidine analogue BrdU, a proliferative cell indicator, strongly suggested PGLRs undergo a transition from appearing in proliferative radial glia in the VZ/SVZ to appearing as GFAP-positive cells in the CP during late-embryonic to early-postnatal stages of developing cortex (see Supplementary Figures S2A-S2C at http://www.BiochemJ.org/bj/419/bj4190565add.htm), which is consistent with the timing of astrogliogenesis in vivo [21, 22] .
Shortly after birth, DIM21-labelled cells were broadly observed in the brain, mainly in cerebral cortex, corpus callosum ( Figure 3G ), striatum, hippocampus and thalamus. These cells displayed elaborate processes ( Figure 3G , inset) and ensheathment of blood vessels ( Figure 3H ), characteristic of mature astroglia [23, 24] . In addition, the DIM21-labelled cells expressed the postnatal astroglial markers GFAP, GLAST and PHGDH ( Figure 3I and see Supplementary Figures S2D and S2E ), but not vice versa, suggesting that a subset of young astroglial populations retain DIM21-reactive PGLRs during the neonatal stage. Moreover, the DIM21-labelled cells were negative for neuronal markers TuJ1 and MAP2 and oligodendroglial markers NG2, MBP and CNPase (results not shown). These cells disappeared completely from postnatal cerebrum by P14. Taken together, these results indicate that DIM21-reactive PGLRs are preferentially expressed in cells of the astroglial lineage in the developing cortex. 
PGLRs are potentially involved in astrogliogenesis from NPCs
We reported previously that treating PGLR-expressing HL60 cells with rGL-7, a human mAb against PtdGlc, induced granulocytic differentiation via activation of Src family protein kinases, Lyn and Hck, within lipid rafts [11] . This finding concurs well with the notion that membrane lipid rafts serve as signalling platforms. Indeed, clustering or cross-linking of specific proteins, including antibodies, causes lipid raft alterations leading to the activation of downstream intracellular signalling cascades [2] . In addition, accumulating evidence shows that radial glia serve as NPCs that ultimately produce neurons and glia during cortical development [21, 25] . The distinct and transient in vivo expression of PGLRs, together with these previous findings, led us to hypothesize that PGLRs play a role in astroglial differentiation in the developing cerebral cortex. Thus we examined how the DIM21-associated effect on PGLRs affects astroglial differentiation using cultured NPCs prepared from fetal telencephalons.
Quantitative RT-PCR and Western blotting analyses demonstrated that treating cultured NPCs with DIM21 caused significant increases in Gfap mRNA and protein expression (Figures 4A and  4B) . NPCs exhibited over 2-fold increases in Gfap mRNA and protein levels in the presence of 10 μg/ml DIM21 compared with untreated or mock-treated NPCs. Immunocytochemical observations also verified substantial induction of GFAP expression in DIM21-treated NPCs ( Figure 4C ).
We also tested whether DIM21 treatment affects NPC proliferation in vitro. We examined how 10 μg/ml DIM21 affects the proliferation of cell spheres derived from single cells from NPC cultures in the absence of extrinsic growth factors. We found that there were no significant changes in the proliferation of the cell spheres irrespective of whether they were treated with DIM21 or not for 6 DIV [DIM21 treatment: 31.73 + − 1.342 μm/diameter; control: 33.45 + − 2.170 μm/diameter; (means + − S.E.M.; n = 20); P = 0.494, Student's t test]. Thus the DIM21-induced modification of PGLRs on NPCs probably directed NPCs to differentiate into GFAP-positive astroglia without affecting cell proliferation.
PGLRs modified by DIM21 mediate Gfap transcription via EGFRs
Precursor cells committed to the astroglial lineage reportedly exist in the developing brain [26] . Increasing evidence shows that several signalling pathways are involved in astroglial differentiation in the rodent CNS [27] . Transcriptional activation of the Gfap gene seems to be a critical step in progenitor cell maturation during astroglial lineage differentiation [28] . To better understand the mechanism underlying DIM21-induced Gfap gene activation in cultured NPCs, we examined whether DIM21 modulates signalling cascades involved in Gfap gene transcription via PGLRs.
When cultured NPCs were treated with 10 μg/ml DIM21, we observed drastic effects on EGFRs. Western blotting demonstrated that a robust and transient increase in tyrosine phosphorylation of EGFRs occurred 0.3 min (18 s) after DIM21 treatment, thereafter returning sharply to basal levels ( Figure 5A ). This was unlikely, but we also observed that EGFR levels increased immediately after DIM21 treatment approx. 3.6-fold (3.63 + − 0.307-fold; n = 8) compared with untreated sample. However, semi-quantitative RT-PCR showed that Egfr mRNA levels were slightly down-regulated 0.3 min after DIM21 treatment before returning to basal levels ( Figure 5B ), suggesting that a cellular mechanism other than the transcriptional activation of Egfr gene was responsible for the DIM21-induced increase in EGFR levels. We speculate that the antibody binding may cause selective solubilization of membrane receptor proteins such as EGFRs, since heat-inactivated DIM21 has no such effects (results not shown).
To test whether PGLRs on NPCs are involved in the DIM21-associated effects on EGFRs, we next examined the localization of PGLRs and EGFRs 0.3 min after treatment with 10 μg/ml DIM21. We found that DIM21 treatment enhanced recruitment of EGFRs into PGLR compartments in the NPCs ( Figure 5C ). In control cultures, approx. 10 % of PGLRs co-localized with EGFRs. In DIM21-treated cultures, however, PGLR-EGFR co-localization increased 2.4-fold. When cultures were treated with 100 ng/ml EGF, PGLR-EGFR complex formation increased 2.8-fold further. However, PGLR-EGFR co-localization was not facilitated by 10 μg/ml anti-EGFR antibody ( Figure 5D ).
We next examined the physical association between PGLRs and EGFRs in DIM21-treated NPCs. When we disrupted PGLRs by depleting plasma membrane cholesterol with MβCD (1.0 and 5.0 mM) [11] , the DIM21-induced increase in EGFR levels as well as the DIM21-induced tyrosine phosphorylation of EGFRs were simultaneously attenuated compared with cells treated only with DIM21. The phosphorylation levels of EGFR were reduced to basal levels ( Figure 5E ). This indicated that PGLRs mediated DIM21-associated effects on EGFRs directly. Furthermore, immunocytochemical analysis indicated that 5.0 mM MβCD pre-treatment for 1 h reduced the levels of both PGLRs and EGFRs on the cell membranes of cultured NPCs ( Figure 5F ). Together, these results strongly suggest that DIM21 treatment activates EGFRs in a ligand-independent, lipid raftdependent manner, and probably mimics in part EGF-dependent modulation of EGFR recruitment into PGLR compartments.
Modified PGLRs drive tyrosine kinase signalling to enhance Gfap transcription
Previous studies using cortical neural stem/progenitor cells in vitro have demonstrated that some signalling molecules play a central role in initiation and/or promotion of Gfap gene expression. These molecules include gp130, JAKs, STATs and Smads [29] [30] [31] . When we examined the effects of DIM21 treatment on these molecules in cultured NPCs, we found that JAK2, a member of the JAK family non-receptor tyrosine kinases, was tyrosine-phosphorylated immediately after treatment ( Figure 6A ). Tyrosine phosphorylation of the signal transducer/transcription activator STAT3, which is mainly tyrosine-phosphorylated and activated by JAK family kinases, was transiently enhanced after DIM21 treatment. Furthermore, Smads (Smad1/Smad5/Smad8) were also synchronously activated, consistent with a recent model of Gfap gene expression in which Smad1 is positively activated in parallel with the JAK/STAT pathway [31] (Figure 6A ). Together, these results demonstrate that PGLRs, modified by DIM21, induce a rapid and transient activation of these intracellular signalling molecules in NPCs in vitro.
Unlike EGFRs, the membrane receptor gp130, a common coreceptor for the interleukin-6 family of cytokines that has been shown to play a pivotal role in inducing GFAP expression [29, 32] , remained unchanged following DIM21 treatment ( Figure 6A ). In addition, PGLR disruption by MβCD failed to alter gp130 levels ( Figure 6B ). Immunocytochemical observations also demonstrated that gp130-PGLR complexes were rarely seen, even after DIM21 treatment (results not shown). It therefore seems unlikely that gp130 is physiologically correlated with the DIM21-induced up-regulation of Gfap gene expression that occurs through PGLRs on NPCs. We also found that Smad phosphorylation levels were notably decreased below basal levels by MβCD treatment ( Figure 6B ).
Together with the data shown in Figure 5 , these results strongly suggest that DIM21-modified PGLRs trigger the rapid recruitment of EGFRs into PGLR compartments, resulting in the enhancement of tyrosine kinase activity of EGFRs without extracellular Cultured NPCs were pre-incubated with the EGFR/JAK2 tyrosine kinase inhibitor AG490 (10 μg/ml) or the EGFR-selective tyrosine kinase inhibitor PD168393 (5.0 μM) in a 5 % CO 2 incubator at 37 • C for 1 h and subsequently subjected to 2 DIV incubation in the presence of each respective inhibitor and/or DIM21 (10 μg/ml). AG490 completely blocked the tyrosine phosphorylation of JAK2 and GFAP expression by inhibiting the JAK/STAT pathway. PD168393 also significantly inhibited the tyrosine phosphorylation of JAK2 and STAT3 and effectively reduced GFAP expression to untreated control levels. Sizes of bands are indicated in kDa.
native ligands. Subsequently, activated EGFRs within PGLRs appear to drive downstream tyrosine kinase signalling cascades, including the JAK/STAT pathway, ultimately leading to enhanced GFAP expression 2 days after treatment.
Activated EGFRs within PGLRs promote GFAP expression via the JAK/STAT pathway
To investigate whether the JAK/STAT pathway was directly involved in the DIM21-induced GFAP up-regulation of cortical NPCs in vitro, we blocked tyrosine phosphorylation signalling using the synthetic kinase inhibitors AG490 (10 μg/ml) [33] or PD168393 (5.0 μM). AG490 is a potent inhibitor of both EGFR [34] and JAK2 [35] , and PD168393 is a specific selective tyrosine kinase inhibitor of EGFR [36] . After pre-incubating cultures with each inhibitor for 1 h, the cultures were subjected to 2 DIV incubation in the presence of the respective inhibitor and/or 10 μg/ml DIM21. Western blotting demonstrated that AG490 completely blocked not only the tyrosine phosphorylation of JAK2, but also GFAP expression by inhibiting the JAK/STAT pathway ( Figure 7) . Moreover, phosphorylation of both STAT3 and Smads was also markedly decreased. PD168393 significantly inhibited the tyrosine phosphorylation of JAK2 and STAT3 and effectively attenuated GFAP expression to untreated control levels. Additionally, phosphorylation of Smads was slightly decreased. Considering that the tyrosine phosphorylation of STAT3 was retained even after AG490 treatment, STAT3 might also be activated via other signalling cascades or maintained by its positive autoregulatory loop mechanism [37] . The decrease in Smad phosphorylation levels seemed to be consistent with the inhibition of JAK/STAT signalling [31] . In addition, since PD168393 decreased GFAP expression in the cultured NPCs to untreated control levels in the presence of DIM21, this strongly suggested that DIM21-induced GFAP up-regulation depends on the activation of EGFRs. Together, these findings demonstrate that EGFR is linked directly to the JAK/STAT pathway and that this cascade plays a major role in the enhanced GFAP expression resulting from DIM21 modification of PGLRs on cortical NPCs.
DISCUSSION EGFR signalling in gliogenesis
Stage-specific EGFRs have been implicated in controlling glial differentiation of multipotent NPCs in vivo during late embryonic to early postnatal stages of brain development [38] [39] [40] . An increase in EGFR cellular content in the germinal zones during late embryonic stages correlated well with shift of cell fate choice from neurogenesis to gliogenesis in cortical NPCs. Whereas cortical NPCs prepared from E10 embryos fail to respond to EGF by proliferating [41] , astroglia-restricted progenitors prepared from E17 embryos respond to EGF by expanding [42] . Consistent with these findings, forced expression of EGFRs in cortical NPCs at an early developmental stage confers cellular competence in response to EGFR ligands, pushing these cells to transition to later NPCs that mainly generate astrocytes [43] . It therefore seems likely that EGFR signalling serves as a regulatory mechanism underlying astrogliogenesis of late NPCs in developing cortex.
In the present study, we clarified the occurrence and astroglial lineage-enriched distribution of PGLRs in the developing cerebral cortex of mice. Our cell culture studies demonstrated that DIM21 modification of PGLRs enhanced Gfap transcription and subsequent astroglial differentiation of cortical NPCs. This fate modulation appears to be associated with increased phosphorylation of certain intracellular signalling molecules, such as JAKs, STATs and Smads. To our surprise, DIM21 treatment elicited a rapid and transient tyrosine phosphorylation of EGFRs and a prolonged elevation of EGFR cellular content in the absence of EGFR ligands. Taken together with previous findings on the role of EGFR and its ligands in neural development, the present findings strongly suggest that PGLRs on radial glia (i.e. cortical NPCs) play a unique role as a signalling platform in astroglial differentiation that is directed via EGFR activation.
Interaction of EGFRs with lipid rafts
Previous studies have shown that EGFRs tend to be partitioned into membrane lipid rafts, where the receptors can be activated [44, 45] . We also observed that when telencephalic cells of E14.5 fetal mice were treated with DIM21, EGFRs were recovered in DIM fractions by phase separation using 0.1 % Triton X-100 at 4
• C (Y. Nagatsuka, M. O. Kinoshita and Y. Hirabayashi, unpublished work). These observations support our finding that EGFRs were recruited rapidly into lipid microdomains enriched in PtdGlc upon DIM21 treatment.
Interestingly, PGLRs isolated from plasma membranes contain very few glycosphingolipids and sphingomyelin [11] . This unusual biochemical feature is also the case for PGLRs derived from cultured NPCs. Immunocytochemical analyses demonstrated that PGLRs co-localize minimally with the G M1 or sphingomyelin on the cell surfaces of cultured NPCs (see Supplementary Figure S3 at http://www.BiochemJ.org/bj/419/bj4190565add.htm). Previously, glycosphingolipid G M3 was shown to interact and negatively modulate the kinase activity of EGFRs [46] . The carbohydrate moiety of G M3 associates with the extracellular domain of EGFR by which EGFR kinase activity is inhibited [47] . The sialic acid residue of G M3 plays an important role in the interplay of G M3 with EGFRs, since overexpressed sialidase in cells reduces the endogenous G M3 content and accordingly enhances EGFR kinase activity [48] . This inhibitory action may be specific to G M3 and not PtdGlc (or its metabolites), since so far no sialylated form of PtdGlc-related lipids has been detected in Nature.
Lipid rafts mainly consist of sphingolipids/phospholipids containing saturated fatty acids and cholesterol, which maintain the liquid-order state [49] . These saturated fatty acid moieties are likely to be involved in mediating selective receptor partitioning into lipid rafts. If this is the case, it seems reasonable that PtdGlc interacts more efficiently with certain proteins in lipid rafts, since the lipid is exclusively composed of doubly saturated fatty acyl chains (C 18:0 /C 20:0 ) [13] . This could confer unique and distinct biophysical properties on PGLRs on plasma membrane. Cholesterol depletion, in general, impairs receptor activation, downstream signal transmission and the cytoskeleton. However, recent studies have shown that EGFRs represent the lone exception in that they are activated in a ligand-independent manner through cholesterol depletion with MβCD [50] . These results are not in agreement with our results from the PtdGlc-lipid raft disruption by MβCD ( Figure 5) . Indeed, our previous study observed no activation of Src family protein kinases in HL60 cells following lipid raft disruption with 1 mM MβCD [11] . Thus we speculate that different protein and lipid components of rafts might distinguish the kinase activity of EGFR or Src family members. Although the exact structural basis for the interaction between PGLRs and EGFRs largely remains elusive, we surmise that lipid rafts are so heterogeneous and different from one cell to another in both lipid components and associated proteins that treatment with MβCD differentially affects EGFR activation.
Multiple mechanisms for astroglial differentiation
Genetic deletion of EGFRs in mice results in massive neurodegeneration in the early postnatal period, accompanied by marked decreases in GFAP-positive cells [51] . Although this study provided in vivo evidence that EGFR signalling plays an important role in astroglial differentiation, some astrocytes still developed in these EGFR-null mice. Astrocytes can be induced in vitro by signals other than EGFR ligands, such as LIF (leukaemia inhibitory factor) [52] , CNTF (ciliary neurotrophic factor) [53] and BMP4 (bone morphogenetic protein 4) [54] . Studies on these extracellular signals have demonstrated further that LIF, CNTF and cardiotrophin-1, all members of the interleukin-6 family of cytokines, activate the JAK/STAT pathway by binding to gp130 and LIF receptors on cortical progenitor cells in embryos [55] [56] [57] , and that activated STAT3 complexes promote transcriptional activation of Gfap by binding to the STAT-binding site on the Gfap promoter [31] . It should be noted that the LIF/gp130-JAK/STAT3 cascade is independent of lipid rafts in embryonic neural precursor cells [58] . Our data also demonstrated that gp130 was not modified by DIM21 treatment, suggesting that PGLRs do not involve the LIF/gp130-JAK/STAT3 pathway for inducing astroglial differentiation.
Together, the findings of the present study are in good agreement with the current concept that multiple mechanisms subserve astroglial differentiation. The present study strongly suggests that one physiological role of PGLRs is to serve as a selective platform for EGFR signalling in late cortical NPCs during timed astrogliogenesis in vivo. It remains unknown, however, to what extent PGLR-EGFR complexes are required for astrogliogenesis in developing cortex. To that end, it is essential to manipulate the PtdGlc content in the nervous system. Further studies aiming at identifying genes/enzymes involved in the synthesis and degradation of PtdGlc are underway. (A) We found that DIM21-labelled cells displayed immature glial morphology in the CP of mouse embryos at E18.5. These cells also weakly expressed GFAP. This immunolabelling suggested PGLR transition, appearing in proliferative radial glia in the germinal VZ/SVZ, then in GFAP-positive glial cells in the CP. To test this hypothesis, we used the thymidine analogue BrdU, a proliferative cell indicator, to label proliferative radial glia in developing cortex and traced BrdU labelling. Timed-pregnant dams were given drinking water containing 1 mg/ml BrdU in two ways: from E15.5 to E18.5 and from E15.5 to P5. Brains were fixed in 4 % (w/v) PFA and sliced into 50-μm-thick sections. The sections were then immersed in 1 M HCl for 30 min at 37 • C and neutralized in 0.1 M boric acid (pH 8.2) for 10 min at room temperature. After washing in 0.1 M PBS, the sections were triple-immunolabelled with rat anti-BrdU antibody (OBT0030, Oxford Biotechnology); DIM21 and rabbit anti-GFAP antibody (N1506; Dako). The BrdU labelling from E15.5 to E18.5 (grey bars) showed three-quarters of GFAP co-expression and about half of simultaneous BrdU co-labelling in the DIM21-labelled cells, whereas the BrdU labelling from E15.5 to P5 (white bars) exhibited 95 % of GFAP co-expression and over 85 % of simultaneous BrdU co-labelling in the cells, strongly suggesting the transition of DIM21-reactive PGLRs, at least in part, from proliferative radial glia into newly generated astroglia during late embryonic to early postnatal stages of developing cortex. This scenario is consistent with the timing of cortical astrogliogenesis in vivo. Immunocytochemical analyses detected very few co-localizations of sphingolipids, G M1 or sphingomyelin (SM), with EGFRs or PGLRs on the cell surfaces of cultured NPCs. In untreated control cultures, the glycosphingolipid G M1 showed approx. 4 % co-localization with EGFRs and 3 % co-localization with PGLRs, whereas SM exhibited 6.8 % co-localization with PGLRs. In DIM21-treated cultures (10.0 μg/ml; 0.3 min), G M1 showed 5.6 % co-localization with EGFRs and 2.7 % co-localization with PGLRs, whereas SM showed 5.8 % co-localization with PGLRs. In general, SM seemed to retain a higher affinity for PGLRs than G M1 . However, neither G M1 nor SM showed substantial enhancement of co-localization with EGFRs or PGLRs after DIM21 treatment.
